Radiopharmaceuticals for the Therapy of Metastatic Bone Pain.
- Author:
Byeong Cheol AHN
1
Author Information
1. Department of Nuclear Medicine, Kyungpook National University Medical School and Kyungpook National University Hospital, Daegu, Korea. abc2000@knu.ac.kr
- Publication Type:Review
- Keywords:
cancer;
osseous metastasis;
bone pain;
pain control;
bone-seeking radiopharmaceuticals;
metabolic radiotherapy
- MeSH:
Analgesics;
Analgesics, Non-Narcotic;
Breast;
Checklist;
Complement System Proteins;
Diphosphonates;
Drug Therapy;
Follow-Up Studies;
Humans;
Hypercalcemia;
Kidney Neoplasms;
Lung;
Neoplasm Metastasis;
Osteoblasts;
Osteoclasts;
Prostate;
Quality of Life;
Radiopharmaceuticals*;
Radiotherapy;
Steroids
- From:Nuclear Medicine and Molecular Imaging
2006;40(2):82-89
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Bone metastasis is a common sequelae of solid malignant tumors such as prostate, breast, lung, and renal cancers, which can lead to various complications, including fractures, hypercalcemia, and bone pain, as well as reduced performance status and quality of life. It occurs as a result of a complex pathophysiologic process between host and tumor cells leading to cellular invasion, migration adhesion, and stimulation of osteoclastic and osteoblastic activity. Several sequelae occur as a result of osseous metastases and resulting bone pain can lead to significant debilitation. A multidisciplinary approach is usually required not only to address the etiology of the pain and its complicating factors but also to treat the patient appropriately. Pharmaceutical therapy of bone pain, includes non-steroidal analgesics, opiates, steroids, hormones, bisphosphonates, and chemotherapy. While external beam radiation therapy remains the mainstay of pain palliation of a solitary lesions, bone seeking radiopharmaceuticals have entered the therapeutic armamentarium for the treatment of multiple painful osseous lesions. 32P, 89SrCl, 153Sm-EDTMP, 188Re/186Re-HEDP, and 177Lu-EDTMP can be used to treat painful osseous metastases. These various radiopharmaceuticals have shown good efficacy in relieving bone pain secondary to bone metastasis. This systemic form of metabolic radiotherapy is simple to administer and complements other treatment options. This has been associated with improved mobility in many patients, reduced dependence on narcotic and non-narcotic analgesics, improved performance status and quality of life, and, in some studies, improved survival. All of these agents, although comprising different physical and chemical characteristics, offer certain advantages in that they are simple to administer, are well tolerated by the patient if used appropriately, and can be used alone or in combination with the other forms of treatment. This article illustrates the salient features of these radiopharmaceuticals, including the usual therapuetic dose, method of administration, and indications for use and also describe about the pre-management checklists, and indication/contraindication and follow-up protocol.
